Dr. Reddy’s introduces ziprasidone mesylate for injection

Print Friendly, PDF & Email

PRINCETON, N.J. — Dr. Reddy’s  has launched ziprasidone mesylate for injection, 20 mg (base)/mL single-dose vials, the therapeutic generic equivalent of Geodon (ziprasidone mesylate) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration.

“We’re pleased to bring the first generic of ziprasidone mesylate for injection to market for patients who will benefit from access to affordable medicine. With every new product launch, we believe we are making healthcare more affordable by delivering value to the pharmacy,” explains Marc Kikuchi, chief executive officer, North America Generics, Dr. Reddy’s Laboratories. “This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio and drive growth within the hospital segment.”

Emerson Industry Day 2022

Comments are closed.

Adheris Health